A recent global study has revealed an alarming disparity in the cost burden of essential medicines, demonstrating that people in poorer countries might be paying more for the same critical drugs compared to those in wealthier nations when adjusted for purchasing power.

The comprehensive analysis, published in 2025, examined 549 essential medicines across 72 countries, drawing on data from various income groups worldwide. While wealthier countries often face higher nominal drug prices, the study highlighted that after considering the local purchasing power, these countries pay significantly less for medicines than lower-income nations.

In poorer regions such as parts of Africa, Southeast Asia, and some low- and middle-income countries, essential medicines can require many days—from several to nearly six weeks—of minimum wage labor to afford one month’s treatment. In contrast, patients in wealthier countries benefit from stronger purchasing power and better access, despite sometimes higher list prices.

Key Findings:

After purchasing power adjustments, drug prices tend to be lower in wealthy countries and higher in poorer nations.

In countries like India, minimum-wage earners may need about 10 days of work to afford certain key medicines.

Chemotherapy drugs and treatments for chronic conditions are especially costly and less affordable in lower-income countries.

Drug availability varies widely, with some countries stocking as few as 225 essential medicines, while others have access to over 400.

The study underscores the urgent need for equitable drug pricing strategies globally, improved affordability, and strengthened healthcare infrastructure to ensure access to life-saving medicines for all populations.

Call to Action:
Experts call for enhanced international cooperation, policy reforms, and market interventions targeted at reducing drug costs in poorer countries. Improving affordability is crucial to advancing health outcomes and achieving universal health coverage goals.